Non-Small Cell Lung Cancer Phase III “ATLAS” Trial Results
Saturday, May 30, 2009 - 13:42
in Health & Medicine
A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III “ATLAS” trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting. According to the National Cancer Institute, in 2008 the estimated number of new lung cancer cases (non-small cell and small cell combined) was 215,000 and the number of deaths was 161,840. Non-small cell lung cancer is the most common among all lung cancers and is usually associated with a history of tobacco use. read more
Read the whole article on Scientific Blogging
More from Scientific Blogging
Related
- Study shows drug combination improves outcome for advanced non-small cell lung cancerSat, 30 May 2009, 11:29:37 EDT
- Vandetanib shows clinical benefit when combined with docetaxel for lung cancerMon, 1 Jun 2009, 9:44:28 EDT
- Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patientsSat, 1 Aug 2009, 15:37:16 EDT
- African American lung cancer patients may have different response to new cancer-fighting drugsWed, 7 Oct 2009, 18:11:47 EDT
- Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapySat, 1 Aug 2009, 15:37:20 EDT